HK Stock Market Move | KEYMED BIO-B(02162) rises more than 3% against the market trend, achieving all research endpoints of the Phase I clinical study of TSLP x IL-13 dual antibody CM512 for atopic dermatitis.

KEYMED BIO-B (02162) rose more than 3% against the market, rising 3.14% to $64.25 Hong Kong dollars as of the time of writing, with a trading volume of HK$49.022 million. In terms of news, according to the official WeChat account of KEYMED BIO-B, on November 4th, the company announced that the global first long-acting TSLP x IL-13 dual inhibitor CM512, independently developed, achieved all the endpoints of the Phase I clinical study in treating moderate to severe atopic dermatitis (AD) in adults. The study showed that CM512 demonstrated rapid disease control capabilities in patients with moderate to severe atopic dermatitis, with features of deep relief and sustained stable efficacy, a half-life of up to 70 days, and good safety, preliminarily reflecting its best-in-class therapeutic potential for moderate to severe atopic dermatitis in adults. CM512 is the global first IgG-like long-acting TSLP x IL-13 dual inhibitor independently developed by CONOVATE, which can simultaneously target TSLP and IL-13, early inhibit the initiation of inflammatory cascade reactions, effectively reduce Th2 cell differentiation and the release of cytokines such as IL-13, and directly inhibit the pathological symptoms driven by IL-13, thus more effectively treating type 2 inflammation-related diseases. Currently, CONOVATE is rapidly advancing the Phase II clinical studies of CM512 for indications such as atopic dermatitis, chronic rhinosinusitis with nasal polyps, asthma, chronic obstructive pulmonary disease, and chronic spontaneous urticaria.